Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy

IF 7.5 2区医学 Q1 IMMUNOLOGY

Immunological Reviews Pub Date : 2023-09-08 DOI:10.1111/imr.13274

Shutong Li, Aoxue Wang, Yongya Wu, Shengyuan He, Wen Shuai, Min Zhao, Yumeng Zhu, Xiuying Hu, Yubin Luo, Guan Wang

{"title":"Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy","authors":"Shutong Li, Aoxue Wang, Yongya Wu, Shengyuan He, Wen Shuai, Min Zhao, Yumeng Zhu, Xiuying Hu, Yubin Luo, Guan Wang","doi":"10.1111/imr.13274","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Non-small-cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small-molecule compounds targeting various types of RCD have shown potential as anticancer treatments. Moreover, RCD appears to be a specific part of the antitumor immune response; hence, the combination of RCD and immunotherapy might increase the inhibitory effect of therapy on tumor growth. In this review, we summarize small-molecule compounds used for the treatment of NSCLC by focusing on RCD and pharmacological systems. In addition, we describe the current research status of an immunotherapy combined with an RCD-based regimen for NSCLC, providing new ideas for targeting RCD pathways in combination with immunotherapy for patients with NSCLC in the future.</p>\n </div>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"321 1","pages":"300-334"},"PeriodicalIF":7.5000,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imr.13274","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Non-small-cell lung cancer (NSCLC), which has a high rate of metastatic spread and drug resistance, is the most common subtype of lung cancer. Therefore, NSCLC patients have a very poor prognosis and a very low chance of survival. Human cancers are closely linked to regulated cell death (RCD), such as apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis. Currently, small-molecule compounds targeting various types of RCD have shown potential as anticancer treatments. Moreover, RCD appears to be a specific part of the antitumor immune response; hence, the combination of RCD and immunotherapy might increase the inhibitory effect of therapy on tumor growth. In this review, we summarize small-molecule compounds used for the treatment of NSCLC by focusing on RCD and pharmacological systems. In addition, we describe the current research status of an immunotherapy combined with an RCD-based regimen for NSCLC, providing new ideas for targeting RCD pathways in combination with immunotherapy for patients with NSCLC in the future.

查看原文本刊更多论文

非小细胞肺癌的靶向治疗：调控细胞死亡与免疫疗法相结合的新见解。

非小细胞肺癌（NSCLC）是肺癌中最常见的亚型，具有高转移扩散率和耐药性。因此，NSCLC 患者的预后很差，生存几率很低。人类癌症与细胞凋亡、自噬、铁凋亡、热凋亡和坏死等调控细胞死亡（RCD）密切相关。目前，针对各种类型 RCD 的小分子化合物已显示出抗癌治疗的潜力。此外，RCD 似乎是抗肿瘤免疫反应的一个特定部分；因此，RCD 与免疫疗法的结合可能会增强疗法对肿瘤生长的抑制作用。在这篇综述中，我们总结了用于治疗 NSCLC 的小分子化合物，重点关注 RCD 和药理系统。此外，我们还介绍了以RCD为基础的免疫疗法联合治疗NSCLC的研究现状，为今后靶向RCD通路联合免疫疗法治疗NSCLC患者提供了新思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunological Reviews 医学-免疫学

CiteScore

16.20

自引率

1.10%

发文量

118

审稿时长

4-8 weeks

期刊介绍： Immunological Reviews is a specialized journal that focuses on various aspects of immunological research. It encompasses a wide range of topics, such as clinical immunology, experimental immunology, and investigations related to allergy and the immune system. The journal follows a unique approach where each volume is dedicated solely to a specific area of immunological research. However, collectively, these volumes aim to offer an extensive and up-to-date overview of the latest advancements in basic immunology and their practical implications in clinical settings.